Celsion Corporation (NASDAQ:CLSN) Stock Is Down 6% In a Week: Here is Why

November 9, 2021

Celsion Corporation (NASDAQ:CLSN) down 6% in a week. The company has announced that EVP and Chief Scientific Officer Khursheed Anwer will present Celsion’s GEN-1 interleukin 12 monotherapy during the Cytokine-Based Cancer Immunotherapies Summit taking place from November 30 to December 2, 2021, in Boston. Trading Data On Monday, CLSN stock went up 0.26% at $0.89 with more than 920K shares, compared to its average volume of 956K shares. The stock…

Read More >>

Celsion Corporation (NASDAQ:CLSN) Stock Jumps 4% in a Week: Here is Why

September 3, 2021

Celsion Corporation (NASDAQ:CLSN) up 4% in a week. The company has announced preclinical in vivo studies results demonstrating antibodies production and cytotoxic T-cell response to SARS-CoV-2 spike antigen in immunization of BALB/c mice with Celsion’s next-gen PLACCIUNE DNA vaccine. Interestingly the SARS-CoV-2 spike antigen antibodies prevented cultured cells infection in a vital neutralization experiment. Thus, the antibodies production shows PLACCINE’s ability to protect against SARS-CoV-2 exposure, and cytotoxic T-cell response…

Read More >>